http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 주제어 : Cell-derived xenograft model (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Kang, Han Na,Choi, Jae Woo,Shim, Hyo Sup,Kim, Jinna,Kim, Dae Joon,Lee, Chang Young,Hong, Min Hee,Park, Seong Yong,Park, A-Young,Shin, Eun Joo,Lee, Seo Yoon,Pyo, Kyoung-Ho,Yun, Mi Ran,Choi, Hun Mi,Lee, Elsevier 2018 Lung cancer Vol.124 No.-
<P><B>Abstract</B></P> <P><B>Background</B></P> <P>Preclinical models that can better predict therapeutic activity in clinical trials are needed in this era of personalized cancer treatment. Herein, we established genomically and clinically annotated patient-derived xenografts (PDXs) from non-small-cell lung cancer (NSCLC) patients and investigated whether these PDXs would faithfully recapitulate patient responses to targeted therapy.</P> <P><B>Methods</B></P> <P>Patient-derived tumors were implanted in immunodeficient mice and subsequently expanded via re-implantation. Established PDXs were examined by light microscopy, genomic profiling, and in vivo drug testing, and the successful engraft rate was analyzed with the mutation profile, histology, or acquisition method. Finally, the drug responses of PDXs were compared with the clinical responses of the respective patients.</P> <P><B>Results</B></P> <P>Using samples from 122 patients, we established 41 NSCLC PDXs [30 adenocarcinoma (AD), 11 squamous cell carcinoma (SQ)], among which the following driver mutation were observed: 13 EGFR-mutant, 4 ALK-rearrangement, 1 ROS1-rearrangement, 1 PIK3CA-mutant, 1 FGFR1-amplification, and 2 KRAS-mutant. We rigorously characterized the relationship of clinical features to engraftment rate and latency rates. The engraft rates were comparable across histologic type. The AD engraft rate tended to be higher for surgically resected tissues relative to biopsies, whereas similar engraft rates was observed for SQ, irrespective of the acquisition method. Notably, EGFR-mutants demonstrated significantly longer latency time than EGFR-WT (86 vs. 37days, P = 0.007). The clinical responses were recapitulated by PDXs harboring driver gene alteration (EGFR, ALK, ROS1, or FGFR1) which regressed to their target inhibitors, suggesting that established PDXs comprise a clinically relevant platform.</P> <P><B>Conclusion</B></P> <P>The establishment of genetically and clinically annotated NSCLC PDXs can yield a robust preclinical tool for biomarker, therapeutic target, and drug discovery.</P> <P><B>Highlights</B></P> <P> <UL> <LI> We established 41 NSCLC PDXs by directly implanting tumor specimens of patients. </LI> <LI> These established PDXs were genetically and clinically annotated. </LI> <LI> The clinical response was recapitulated by PDXs. </LI> <LI> PDXs is a robust tool for biomarker, therapeutic target, and drug discovery. </LI> </UL> </P>
-
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
